### Indication
<table>
<thead>
<tr>
<th>INN</th>
<th>Enalapril</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medicine type</td>
<td>Chemical agent</td>
</tr>
<tr>
<td>List type</td>
<td>Core</td>
</tr>
</tbody>
</table>

### Formulations
- Oral > Solid > tablet: 2.5 mg (as hydrogen maleate); 5 mg (as hydrogen maleate); 10 mg (as hydrogen maleate)

### EML status history
- First added in 2003 (TRS 920)
- Changed in 2009 (TRS 958)
- Changed in 2021 (TRS 1035)
- Changed in 2023 (TRS 1049)

### Sex
- All

### Age
- Adolescents and adults

### Therapeutic alternatives
- Medicines within the same pharmacological class can be used

### Therapeutic alternatives limitations
- Therapeutic alternatives are medicines in the 4th level ATC chemical subgroup: C09AA ACE inhibitors, plain.

### Patent information
- Patents have expired in most jurisdictions

### Wikipedia
- Enalapril

### DrugBank
- Enalapril

### Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the addition of enalapril 10 mg tablets to the EML and EMLc and the addition of enalapril 1 mg/mL oral liquid to the EMLc.